Showing results (311-320 of 365) with videos related to

Sort By:
Pageof 37
American Journal of Surgery|January 8, 2021
Self-advocacy is associated with lower likelihood of living donor kidney transplantationA Cozette Killian, Rhiannon D Reed, Alexis Carter, et al.
Leukemia|June 4, 2010
Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanismR A Hamoudi, A Appert, H Ye, et al.
Annals of Surgery|July 27, 2019
Mitigating Racial and Sex Disparities in Access to Living Donor Kidney Transplantation: Impact of the Nation's Longest Single-center Kidney ChainMargaux N Mustian, Vineeta Kumar, Katie Stegner, et al.
Surgery|August 25, 2019
Donation approval among obese living kidney donor candidates: The impact of metabolic syndromeMargaux N Mustian, Vineeta Kumar, Michael Hanaway, et al.
Vaccines|April 23, 2022
Pivotal Shigella Vaccine Efficacy Trials-Study Design Considerations from a Shigella Vaccine Trial Design Working GroupPatricia B Pavlinac, Elizabeth T Rogawski McQuade, James A Platts-Mills, et al.
International Journal of Cosmetic Science|February 28, 2009
Collaborative development of a sun protection factor test method: a proposed European Standard. COLIPA Task Force 'Sun Protection Measurement', EuropeJ Ferguson, M Brown, D Alert, et al.
Vaccine|May 3, 2025
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countriesAna Belen Ibarz-Pavon, Marie-Christine Bielsky, Rubina Bose, et al.
The Journal of Clinical Investigation|March 22, 2008
The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African childrenCalman A MacLennan, Esther N Gondwe, Chisomo L Msefula, et al.
Vaccine|May 4, 2020
Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019Sami L Gottlieb, Francis Ndowa, Edward W Hook, et al.
British Journal of Cancer|July 1, 1996
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation reportD C Linch, B Vaughan Hudson, B W Hancock, et al.
Pageof 37